調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023

オートインジェクターの世界市場予測（～2023年）：関節リウマチ、多発性硬化症、アナフィラキシー、心臓血管疾患、乾癬、片頭痛

◆タイトル：Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023
◆商品コード：MD6494
◆調査・発行会社：MarketsandMarkets
◆発行日：2018年8月1日
◆ページ数：134
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医療機器
◆販売価格オプション（消費税別）

Single User（1名利用）	USD5,650 ⇒換算￥723,200	見積依頼/購入/質問フォーム
Multi User (Five User)	USD6,650 ⇒換算￥851,200	見積依頼/購入/質問フォーム
Corporate License (全社内共有可)	USD8,150 ⇒換算￥1,043,200	見積依頼/購入/質問フォーム

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarketsが発行した当調査レポートでは、オートインジェクターの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、治療別（関節リウマチ、多発性硬化症、アナフィラキシー、心臓血管疾患、乾癬、片頭痛）分析、タイプ別（使い捨て、再利用）分析、エンドユーザー別（在宅医療、病院）分析、オートインジェクターの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global autoinjectors market is projected to reach USD 85.31 billion by 2023 from USD 28.91 billion in 2018 at a CAGR of 24.2% during the forecast period. The growth of this market is primarily driven by factors such as the growing prevalence of targeted therapies, rising incidence of anaphylaxis, increasing number of regulatory approvals, and the availability of generic versions of autoinjectors.
The autoinjectors market is segmented on the basis of therapy, type, end user, and region. Based on therapy, the global autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therapies (such as migraines, cardiovascular diseases, psoriasis, and anemia). The rheumatoid arthritis segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the high prevalence of rheumatoid arthritis across the globe.

Based on type, the market is segmented into disposable and reusable autoinjectors. The disposable autoinjectors segment is expected to grow at the highest CAGR during the forecast period. The high growth of this segment can be attributed to the benefits disposable autoinjectors offer, such as portability, ease of use, and low possibility of infection.

Based on end user, the global autoinjectors market is categorized into home care settings and hospital & clinics. The home care settings segment is expected to register the highest CAGR during the forecast period due to the growing demand for self-administration drug delivery devices and the growing prevalence of chronic diseases.

Geographic segments in this report include North America, Europe, Asia Pacific, and RoW. Of these, the North American region is expected to account for the largest share of the market in 2018. The large share of this region can be attributed to the rising prevalence of autoimmune and chronic diseases, rising prevalence of anaphylaxis, and favorable reimbursement scenario in this region.

Autoinjectors Market

Preference for alternative drug delivery modes such as oral diabetic agents and epinephrine nasal sprays is expected to restrain the growth of this market during the forecast period to a certain extent.

The global autoinjectors market is dominated by Abbvie (US), Amgen (US), Teva (Israel), Biogen (US), Eli Lilly (US), and Mylan (US). These players adopted growth strategies such as product launches, product approvals, agreements and expansions to maintain and enhance their position in the market. Other prominent players in the market include Ypsomed (Switzerland), Merck (Germany), AstraZeneca (UK), J&J (US), Bayer (Germany), Becton, Dickinson and Company (US), Owen Mumford (UK), Novartis (Switzerland), and Haselmeier (Switzerland).

【レポートの目次】

1 Introduction (Page No. – 14)
1.1 Objectives of Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Years Considered for the Study
1.3.2 Markets Covered
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 17)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.2.1 Key Data From Primary Sources
2.2.2.2 Key Industry Insights
2.3 Market Size Estimation Methodology
2.4 Market Data Validation and Triangulation
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 27)

4 Premium Insights (Page No. – 31)
4.1 Autoinjectors Market Overview
4.2 Autoinjectors Market, By Type, 2018 vs 2023
4.3 Geographic Analysis: Autoinjectors Market, By Therapy
4.4 Autoinjectors Market, By End User, 2018 vs 2023
4.5 Geographic Snapshot: Autoinjectors Market

5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Prevalence of Targeted Therapies
5.2.1.2 Rising Incidence of Anaphylaxis
5.2.1.3 Increasing Number of Regulatory Approvals
5.2.1.4 Availability of Generic Versions of Autoinjectors
5.2.1.5 Favorable Reimbursements and Government Support
5.2.1.6 Technological Advancements and Design Development
5.2.2 Restraints
5.2.2.1 Preference for Alternative Drug Delivery Modes
5.2.2.1.1 Oral Diabetic Agents and Oral Insulin
5.2.2.1.2 Epinephrine Nasal Sprays
5.2.3 Opportunities
5.2.3.1 Patent Expiry of Biologics to Drive the Demand for Biosimilars
5.2.4 Challenges
5.2.4.1 Development of Autoinjectors for Multiple Drug Viscosities
5.2.4.2 Lack of Proper Training for Using Autoinjectors

6 Autoinjectors Market, By Therapy (Page No. – 42)
6.1 Introduction
6.2 Rheumatoid Arthritis
6.3 Multiple Sclerosis
6.4 Diabetes
6.5 Anaphylaxis
6.6 Other Therapies

7 Autoinjectors Market, By Type (Page No. – 50)
7.1 Introduction
7.2 Disposable Autoinjectors
7.3 Reusable Autoinjectors

8 Autoinjectors Market, By End User (Page No. – 55)
8.1 Introduction
8.2 Home Care Settings
8.3 Hospitals & Clinics

9 Autoinjectors Market, By Region (Page No. – 60)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 RoAPAC
9.5 Rest of the World

10 Competitive Landscape (Page No. – 94)
10.1 Overview
10.2 Market Share Analysis
10.3 Market Ranking of OEM Companies
10.4 Market Share Analysis, By Therapeutic Area
10.4.1 Rheumatoid Arthritis
10.4.2 Multiple Sclerosis
10.4.3 Diabetes
10.4.4 Anaphylaxis
10.5 Competitive Scenario
10.5.1 Product Launches and Approvals
10.5.2 Expansions
10.5.3 Agreements, Collaborations, and Partnerships

11 Company Profiles (Page No. – 101)
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.1 Abbvie
11.2 Mylan
11.3 ELI Lilly
11.4 Ypsomed
11.5 Amgen
11.6 Becton, Dickinson and Company
11.7 Owen Mumford
11.8 Consort Medical
11.9 Haselmeier
11.10 Shl Group (Scandinavian Health Limited)
11.11 Johnson & Johnson (J&J)
11.12 Teva
11.13 Antares Pharma

*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.

12 Appendix (Page No. – 125)
12.1 Discussion Guide
12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.3 Available Customizations
12.4 Related Reports
12.5 Author Details

List of Tables (66 Tables)

Table 1 Recent Approvals of Autoinjector Devices Across the Globe
Table 2 Patent Expiry of Key Biologics
Table 3 Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 4 Autoinjectors Market for Rheumatoid Arthritis, By Country, 2016–2023 (USD Billion)
Table 5 Autoinjectors Market for Multiple Sclerosis, By Country, 2016–2023 (USD Billion)
Table 6 Autoinjectors Market for Diabetes, By Country, 2016–2023 (USD Million)
Table 7 Autoinjectors Market for Anaphylaxis, By Country, 2016–2023 (USD Million)
Table 8 Autoinjectors Market for Other Therapies, By Country, 2016–2023 (USD Million)
Table 9 Comparison of Disposable & Reusable Autoinjectors
Table 10 Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 11 Disposable Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 12 Reusable Autoinjectors Market, By Country, 2016–2023 (USD Million)
Table 13 Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 14 Autoinjectors Market for Home Care Settings, By Country, 2016–2023 (USD Billion)
Table 15 Autoinjectors Market for Hospitals & Clinics, By Country, 2016–2023 (USD Million)
Table 16 Autoinjectors Market, By Region, 2016–2023 (USD Billion)
Table 17 North America: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 18 North America: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 19 North America: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 20 North America: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 21 Autoinjectors Approved By the Fda, 2015–2018
Table 22 US: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 23 US: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 24 US: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 25 Canada: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 26 Canada: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 27 Canada: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 28 Product Approvals in Europe, 2015–2018
Table 29 Europe: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 30 Europe: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 31 Europe: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 32 Europe: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 33 Germany: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 34 Germany: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 35 Germany: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 36 UK: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 37 UK: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 38 UK: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 39 France: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 40 France: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 41 France: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 42 RoE: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 43 RoE: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 44 RoE: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 45 Asia Pacific: Autoinjectors Market, By Country, 2016–2023 (USD Billion)
Table 46 Asia Pacific: Autoinjectors Market, By Therapy, 2016–2023 (USD Billion)
Table 47 Asia Pacific: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 48 Asia Pacific: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 49 Japan: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 50 Japan: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 51 Japan: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 52 China: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 53 China: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 54 China: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 55 India: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 56 India: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 57 India: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 58 RoAPAC: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 59 RoAPAC: Autoinjectors Market, By Type, 2016–2023 (USD Million)
Table 60 RoAPAC: Autoinjectors Market, By End User, 2016–2023 (USD Million)
Table 61 RoW: Autoinjectors Market, By Therapy, 2016–2023 (USD Million)
Table 62 RoW: Autoinjectors Market, By Type, 2016–2023 (USD Billion)
Table 63 RoW: Autoinjectors Market, By End User, 2016–2023 (USD Billion)
Table 64 Product Launches and Approvals
Table 65 Expansions
Table 66 Agreements, Collaborations, and Partnerships

List of Figures (36 Figures)

Figure 1 Autoinjectors Market: Research Methodology Steps
Figure 2 Break Down of Primary Interviews: By Company Type, Designation, and Region
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Research Design
Figure 6 Data Triangulation Methodology
Figure 7 Rheumatoid Arthritis Therapy Segment to Dominate the Autoinjectors Market in 2018
Figure 8 Disposable Autoinjectors to Account for the Largest Share of the Autoinjectors Market in 2018
Figure 9 Home Care Settings to Dominate the Autoinjectors Market During the Forecast Period
Figure 10 North America to Witness the Highest Market Growth During the Forecast Period
Figure 11 Growing Prevalence of Targeted Therapies and Increasing Number of Regulatory Approvals are Driving Market Growth
Figure 12 Disposable Autoinjectors to Dominate the Market in 2018
Figure 13 Rheumatoid Arthritis Therapy Segment to Command the Largest Share of the Autoinjectors Market in 2018
Figure 14 Home Care Settings to Account for the Largest Market Share in 2018
Figure 15 North America to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Autoinjectors Market: Drivers, Restraints, Opportunities, & Challenges
Figure 17 Autoinjectors Market, By Therapy, 2018 vs 2023 (USD Billion)
Figure 18 Autoinjectors Market, By Type, 2018 vs 2023 (USD Billion)
Figure 19 Autoinjectors Market, By End User, 2018 vs 2023 (USD Billion)
Figure 20 North America to Command the Largest Market Share in 2018
Figure 21 North America: Autoinjectors Market Snapshot
Figure 22 Europe: Autoinjectors Market Snapshot
Figure 23 Asia Pacific: Autoinjectors Market Snapshot
Figure 24 RoW: Autoinjectors Market Snapshot
Figure 25 Market Ranking of OEM Companies
Figure 26 Strategies Adopted By Market Players (2014–2018)
Figure 27 Abbvie: Company Snapshot (2017)
Figure 28 Mylan: Company Snapshot (2017)
Figure 29 ELI Lilly: Company Snapshot (2017)
Figure 30 Ypsomed: Company Snapshot (2017)
Figure 31 Amgen: Company Snapshot (2017)
Figure 32 BD: Company Snapshot (2017)
Figure 33 Consort Medical: Company Snapshot (2017)
Figure 34 Johnson & Johnson: Company Snapshot (2017)
Figure 35 Teva: Company Snapshot (2017)
Figure 36 Antares Pharma: Company Snapshot (2017)

★調査レポート[オートインジェクターの世界市場予測（～2023年）：関節リウマチ、多発性硬化症、アナフィラキシー、心臓血管疾患、乾癬、片頭痛] ( Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023 / MD6494) 販売に関する免責事項

[オートインジェクターの世界市場予測（～2023年）：関節リウマチ、多発性硬化症、アナフィラキシー、心臓血管疾患、乾癬、片頭痛] ( Autoinjectors Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, Cardiovascular diseases, Psoriasis, Migraine), Type (Disposable, and Reusable), End Users (Homecare, and Hospitals) - Global Forecast to 2023 / MD6494) についてEメールでお問い合わせ

◆H&Iグローバルリサーチ株式会社のお客様（例）◆